|
Product | Quantum (Rs. Cr) | Long Term Rating | Short Term Rating |
Issuer Rating (IR) | 0.00 | ACUITE B | Stable | Downgraded | - |
Total Outstanding | 0.00 | - | - |
Rating Rationale |
Acuite has downgraded its long-term issuer rating (IR) to 'ACUITE B' (read as ACUITE B) from ‘ACUITE BBB+(IR)’ (read as ACUITE triple B plus(Issuer Rating)) of Aaquaries Global Industries Limited(AGIL). The outlook is 'Stable'. |
About Company |
Incorporated in 2007 by Mr. Rajendra Kamat, Mumbai-based Aaquaries Global Industries Limited (AGIL) is currently owned and operated by Mr. Sameer Talim, along with Mr. Ravi Kumar and Mr. Austin Dsouza. The company is engaged in manufacturing and trading of active pharmaceutical ingredients (API) and Intermediates. The Company mainly caters to anticancer and anti-infective APIs. The Company along with its wholly owned subsidiary Aaquaries Global Industries Limited (Dubai) owns around 14 registered patents for producing anticancer, pain killers and infective API’s. |
About the Group |
Aaquaries Group consists of Mumbai based Aaquaries Global Industries Limited and Dubai based wholly owned subsidiary Aaquaries Global Industries Limited (Dubai). The two entities are together engaged in manufacturing and trading of APIs and Intermediates and are managed by Mr. Sameer Ramesh Talim, Mr. Ravi Kumar, Mr. Austin Dsouza. |
Unsupported Rating |
Not Applicable |
Analytical Approach |
Extent of Consolidation |
•Full Consolidation |
Rationale for Consolidation or Parent / Group / Govt. Support |
The team has considered the consolidated approach of Aaquaries Global Industries Limited and its wholly owned subsidiary- Aaquaries Global Industries Limited(Dubai) due to strong operational and financial linkages as well as common management. |
Key Rating Drivers |
Strengths |
Established track record of operations
Aaquaries Group, under its flagship company AGIL, commenced operations in the year 2007 reflecting an established track record of operations for more than one decade. The group is managed by Mr. Sameer Talim, who has more than 10 years of experience in the pharmaceuticals business |
Weaknesses |
Material misstatement in information shared by issuer |
Rating Sensitivities |
Misrepresentation of information. |
All Covenants |
Not Applicable |
Liquidity position: Adequate |
The group has an adequate liquidity position marked by sufficient net cash accruals against negligible maturing debt obligations. |
Outlook: |
The outlook may be revised to 'Positive' in case of significant improvement in the scale of operations and profitability along with clarity regarding the misstatements observed in the information. Conversely, the outlook may be revised to 'Negative' in case of deterioration in the financial risk profile of the Group or elongation of the working capital cycle and any negative information in the public domain. |
Other Factors affecting Rating |
None |
Particulars | Unit | FY 23 (Actual) | FY 22 (Actual) |
Operating Income | Rs. Cr. | 1894.87 | 1281.17 |
PAT | Rs. Cr. | 202.25 | 127.64 |
PAT Margin | (%) | 10.67 | 9.96 |
Total Debt/Tangible Net Worth | Times | 0.01 | 0.00 |
PBDIT/Interest | Times | 43.02 | 368.04 |
Status of non-cooperation with previous CRA (if applicable) |
Not Applicable |
Any Other Information |
None |
Applicable Criteria |
• Application Of Financial Ratios And Adjustments: https://www.acuite.in/view-rating-criteria-53.htm • Consolidation Of Companies: https://www.acuite.in/view-rating-criteria-60.htm • Default Recognition: https://www.acuite.in/view-rating-criteria-52.htm • Manufacturing Entities: https://www.acuite.in/view-rating-criteria-59.htm |
Note on Complexity Levels of the Rated Instrument |
In order to inform the investors about complexity of instruments, Acuité has categorized such instruments in three levels: Simple, Complex and Highly Complex. Acuite’ s categorisation of the instruments across the three categories is based on factors like variability of the returns to the investors, uncertainty in cash flow patterns, number of counterparties and general understanding of the instrument by the market. It has to be understood that complexity is different from credit risk and even an instrument categorized as 'Simple' can carry high levels of risk. For more details, please refer Rating Criteria “Complexity Level Of Financial Instruments” on www.acuite.in. |
|
|
|
||||||||||||||||||
|
Contacts |
|
|
About Acuité Ratings & Research |
© Acuité Ratings & Research Limited. All Rights Reserved. | www.acuite.in |